Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Gefitinib Recurrence Carcinoma, Non-Small-Cell Lung
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 23
Healthy volunteers: no

Brief summary:
A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous gefitinib failure.

Primary endpoint

* to assess Disease Control Rate (Remission + Stable disease)

Secondary endpoints

* to assess the progression free survival

Detailed description:

Arms:
arm 1: Gefitinib retreatment

Interventions: intervention 1: Gefitinib retreatment
Intervention descriptions: intervention 1: phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.

Protocol document: